Insights

Diversified Product Pipeline Ocular Therapeutix has a diverse product pipeline, including FDA-approved products like DEXTENZA for ocular inflammation and pain, offering multiple entry points for sales discussions across various eye-related conditions.

Strategic Equity Financing With recent strategic equity financing of $325 million, Ocular Therapeutix has the necessary backing to expand its commercialization efforts and potentially seek new partnerships or collaborations that could result in increased sales opportunities.

New Chief Commercial Officer The appointment of Steve Meyers as Chief Commercial Officer showcases Ocular Therapeutix's focus on accelerating commercial activities. Engaging with the new CCO could open avenues for strategic sales initiatives and market expansion.

Key Clinical Programs Focused on developing drug candidates for eye disorders, Ocular Therapeutix's lead clinical program AXPAXLI aims to treat wet AMD and diabetic retinopathy. Sales teams could leverage the upcoming results from the HELIOS study to drive discussions with potential healthcare providers.

Investment and Growth The recent investment by Erste Asset Management GmbH and successful financing demonstrate investor confidence in Ocular Therapeutix's potential. Sales professionals can leverage this positive market sentiment to build relationships and explore new sales opportunities.

Similar companies to Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. Tech Stack

Ocular Therapeutix, Inc. uses 8 technology products and services including Pentaho, Shopify, Prototype, and more. Explore Ocular Therapeutix, Inc.'s tech stack below.

  • Pentaho
    Business Intelligence
  • Shopify
    E-commerce
  • Prototype
    Javascript Frameworks
  • OWL Carousel
    Javascript Libraries
  • Module Federation
    Miscellaneous
  • Greenhouse
    Recruitment Marketing
  • MediaElement.js
    Video Players
  • Minitab
    Visualisation Software

Media & News

Ocular Therapeutix, Inc.'s Email Address Formats

Ocular Therapeutix, Inc. uses at least 1 format(s):
Ocular Therapeutix, Inc. Email FormatsExamplePercentage
FLast@ocutx.comJDoe@ocutx.com
96%
Last@ocutx.comDoe@ocutx.com
3%
FL@ocutx.comJD@ocutx.com
1%

Frequently Asked Questions

Where is Ocular Therapeutix, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc.'s main headquarters is located at 15 Crosby Drive Bedford, MA 01730 US. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is Ocular Therapeutix, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Ocular Therapeutix, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ocular Therapeutix, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc. is a publicly traded company; the company's stock symbol is OCUL.

What is Ocular Therapeutix, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc.'s official website is ocutx.com and has social profiles on LinkedIn.

How much revenue does Ocular Therapeutix, Inc. generate?

Minus sign iconPlus sign icon
As of December 2024, Ocular Therapeutix, Inc.'s annual revenue reached $35M.

What is Ocular Therapeutix, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc.'s SIC code is 2834 - Pharmaceutical Preparations NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Ocular Therapeutix, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2024, Ocular Therapeutix, Inc. has approximately 288 employees across 5 continents, including North AmericaEuropeAsia. Key team members include Chief Business Officer: C. W.Chief Financial Officer: D. N.Chief Commercial Officer: S. M.. Explore Ocular Therapeutix, Inc.'s employee directory with LeadIQ.

What industry does Ocular Therapeutix, Inc. belong to?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does Ocular Therapeutix, Inc. use?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc.'s tech stack includes PentahoShopifyPrototypeOWL CarouselModule FederationGreenhouseMediaElement.jsMinitab.

What is Ocular Therapeutix, Inc.'s email format?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc.'s email format typically follows the pattern of . Find more Ocular Therapeutix, Inc. email formats with LeadIQ.

How much funding has Ocular Therapeutix, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2024, Ocular Therapeutix, Inc. has raised $325M in funding. The last funding round occurred on Feb 22, 2024 for $325M.

When was Ocular Therapeutix, Inc. founded?

Minus sign iconPlus sign icon
Ocular Therapeutix, Inc. was founded in 2006.
Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

Pharmaceutical ManufacturingMassachusetts, United States201-500 Employees

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.

Section iconCompany Overview

Headquarters
15 Crosby Drive Bedford, MA 01730 US
Phone number
Website
ocutx.com
SIC Code
2834 - Pharmaceutical Preparations
Stock Symbol
OCUL
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2006
Employees
201-500

Section iconFunding & Financials

  • $325M

    Ocular Therapeutix, Inc. has raised a total of $325M of funding over 12 rounds. Their latest funding round was raised on Feb 22, 2024 in the amount of $325M.

  • $10M$50M

    Ocular Therapeutix, Inc.'s revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $325M

    Ocular Therapeutix, Inc. has raised a total of $325M of funding over 12 rounds. Their latest funding round was raised on Feb 22, 2024 in the amount of $325M.

  • $10M$50M

    Ocular Therapeutix, Inc.'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.